Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

647
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
647
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

171
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
171
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

220
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
220
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

153
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
153
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

371
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
371

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex- and Age-Dependent Outcomes of Cryoablation in Atrial Fibrillation: A 3- and 6-Month Post-Procedural QoL Analysis.

Journal of arrhythmia·2026
Same author

Mast Cells and Cardiovascular Disorders.

Current vascular pharmacology·2026
Same author

Occupational and Environment-Related Cardiovascular Disease: A Comprehensive Review of the Literature.

Current vascular pharmacology·2026
Same author

Chocolate and Cardiovascular Disease.

Cardiology in review·2026
Same author

The Kallikrein-Kinin System and Cardiovascular Diseases: A Narrative Review.

Angiology·2026
Same author

The Use of Colchicine in Cardiovascular Disease: Anti-Inflammatory Mechanisms and Clinical Utility.

Current vascular pharmacology·2026
Same journal

Extracellular Matrix-Related Prognostic Signature for Head and Neck Squamous Cell Carcinoma via Multi-Algorithm Survival Modeling.

Biomarker insights·2026
Same journal

Salivary Biomarkers for Diagnosis and Monitoring of Thyroid Diseases: A Systematic Review of Current Evidence.

Biomarker insights·2026
Same journal

Urinary Calprotectin Predicts Severe Acute Kidney Injury After Non-cardiac Surgery in Surgical Intensive Care Unit: A Prospective Cohort Study.

Biomarker insights·2026
Same journal

Insight to Neglected Biomarkers in COVID-19: A Comprehensive Narrative Review".

Biomarker insights·2026
Same journal

Bacterial Fluorescence-Based Biosensor for Detecting Propionate in Culture Media for Diagnostic Applications.

Biomarker insights·2026
Same journal

Translating Liquid Biopsy into Practice- The Promise and Challenges of Circulating Tumor Cells in Ovarian and Lung Cancer Management.

Biomarker insights·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

Are We Using Ezetimibe As Much As We Should?

Antonis A Manolis1, Theodora A Manolis2, Dimitri P Mikhailidis3

  • 1Cardiology Department, Evagelismos Hospital, Athens, Greece.

Biomarker Insights
|June 3, 2024
PubMed
Summary
This summary is machine-generated.

Ezetimibe is an effective and affordable lipid-lowering therapy, often used with statins to reach low-density lipoprotein cholesterol (LDL-C) goals. It improves cardiovascular outcomes and is a good alternative for statin-intolerant patients.

Keywords:
Ezetimibecardiovascular diseasecholesterolcoronary artery diseasedyslipidemialipidslipoproteinmyocardial infarction

More Related Videos

Optimization of the Epimedii Folium Mutton-Oil Processing Technology and Testing Its Effect on Zebrafish Embryonic Development
06:00

Optimization of the Epimedii Folium Mutton-Oil Processing Technology and Testing Its Effect on Zebrafish Embryonic Development

Published on: March 17, 2023

462
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.0K

Related Experiment Videos

Last Updated: Jun 24, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K
Optimization of the Epimedii Folium Mutton-Oil Processing Technology and Testing Its Effect on Zebrafish Embryonic Development
06:00

Optimization of the Epimedii Folium Mutton-Oil Processing Technology and Testing Its Effect on Zebrafish Embryonic Development

Published on: March 17, 2023

462
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.0K

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Many patients with atherosclerotic cardiovascular disease (CVD) do not achieve target low-density lipoprotein cholesterol (LDL-C) levels with statin therapy alone.
  • Statin-associated adverse effects limit their widespread use and optimal management of CVD.
  • Non-statin lipid-lowering therapies are underutilized despite the unmet need for effective CVD risk reduction.

Purpose of the Study:

  • To provide a comprehensive review of ezetimibe's effects on lipid lowering, cardiovascular (CV) event reduction, and outcome improvement.
  • To evaluate ezetimibe as a monotherapy or in combination with statins for managing dyslipidemia and reducing CVD risk.
  • To assess ezetimibe's role as an alternative treatment for patients with statin intolerance.

Main Methods:

  • Review of clinical trial data and outcomes studies on ezetimibe.
  • Analysis of ezetimibe's efficacy in monotherapy and combination therapy with statins.
  • Evaluation of ezetimibe's safety and tolerability profile compared to other lipid-lowering agents.

Main Results:

  • Ezetimibe, as oral monotherapy or combined with statins, is an effective and affordable option for achieving LDL-C goals.
  • Combination therapy with ezetimibe and statins enhances lipid-lowering effects (approx. 20%) and allows for lower statin doses, reducing side effects.
  • Ezetimibe demonstrates efficacy in reducing CVD risk and events, supported by cardiovascular outcomes data.

Conclusions:

  • Ezetimibe is a convenient and effective first-line add-on therapy to statins for achieving LDL-C targets.
  • It offers an excellent safety and tolerability profile, enhancing lipid-lowering effects and potentially mitigating statin-related side effects.
  • Ezetimibe serves as a valuable alternative treatment option for patients unable to tolerate statins, contributing to improved CVD management.